References
- American Psychiatric Association. Force diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington (DC): American Psychiatric Association; 2013.
- Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012 Jul;9(3):490–499. PubMed PMID: 22976615; PubMed Central PMCID: PMCPMC3441936.
- Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894–921. PubMed PMID: 17581453.
- Wolraich M, Brown L, Brown RT, et al.; Subcommittee on Attention-Deficit/Hyperactivity D, Steering Committee on Quality I, Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011 Nov;128(5):1007–1022. PubMed PMID: 22003063; PubMed Central PMCID: PMCPMC4500647.
- Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010 Apr;19(4):353–364. PubMed PMID: 19763664.
- Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry. 1937;94:577–585.
- Gautam M, Prabhakar D. Stimulant formulations for the treatment of attention-deficit/hyperactivity disorder. Prim Care Companion CNS Disord. 2018 Dec 27;20(6). PubMed PMID: 30605269. DOI: 10.4088/PCC.18r02345.
- CONCERTA (methylphenidate HCl) extended-release tablets, CII. Highlights of Prescribing Information [cited 2019 April 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021121s038lbl.pdf
- Jones DF, McRea AR, Jairath MK, et al. Prospective assessment of pill-swallowing ability in pediatric patients. Clin Pediatr (Phila). 2018 Mar;57(3):300–306. PubMed PMID: 28770624.
- Empty Capsule Size Chart [cited 2019 Apr 21]. Available from: https://capsuline.com/pages/empty-capsule-size-chart
- Once Daily Metadate CD (Methylphenidate HCl, USP) Extended-Release Capsules [cited 2019 Apr 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021259s030lbl.pdf
- Ritalin LA (Methylphenidate Hydrochloride) extended-release capsules [cited 2019 Apr 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021284s016s029lbl.pdf
- Focalin XR (Dexmethylphenidate hydrochloride) extented-release capsules. Highlights of Prescribing Information [cited 2019 Apr 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021802s019s029lbl.pdf
- Aptensio XR (Methylphenidate hydrochloride extended-release) capsules for oral use, CII. Highlights of prescribing information [cited 2019 Apr 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205831s003lbl.pdf
- Quillivant XR (Methylphenidate hydrochloride) for extended-release oral suspension. Highlights of Prescribing Information. [cited 2019 Apr 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202100s006lbl.pdf
- NDA 202100. NDA approval Quillivant XR. NextWave Pharmaceuticals, Inc [cited 2019 Apr 7]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202100
- NDA 208147. NDA approval Dyanavel XR. Tris Pharma [cited 2019 Apr 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/208147Orig1s000ltr.pdf
- NDA 207960. NDA approval Quillichew ER. Pfizer [cited 2019 Apr 7]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207960
- NDA 204326. NDA approval Adzenys XR ODT. Neos Therapeutics, Inc [cited 2019 Apr 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/204326Orig1s000ltr.pdf
- NDA 205489. NDA approval Cotempla XR ODT. Neos Therapeutics, Inc [cited 2019 Apr 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/205489Orig1s000ltr.pdf
- NDA 204325. NDA approval Adzenys ER oral suspension. Neos Therapeutics, Inc [cited 2019 Apr 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/204325Orig1s000ltr.pdf
- NDA 208150. NDA approval Vyvanse chewable tablets. Shire Development, LLC [cited 2019 Apr 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208510Orig1s000ltr.pdf
- Dyanavel XR (Amphetamine) extended-release oral suspension, CII. Highlights of Prescribing Information [ cited 2019 Apr 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208147s005lbl.pdf
- Herman BK, King TR, Kando JC, et al. A novel, modified-release drug delivery technology containing amphetamine ion-exchange complexes. American Professional Society for ADHD and RElated Disorders Annual Meeting; 2019 Jan 18; Washington (DC).
- Center for Drug Evaluation and Research Application Number: 208147Orig1s000 Chemistry Review(s) [cited 2019 Apr 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208147Orig1s000ChemR.pdf
- Berry S, Belden H Single-dose pharmacokinetics of amphetamine extended-release oral suspension (AMPH EROS) compared with immediate-release mixed amphetamine salts. The American Professional Society of ADHD and Releated Disorders; 2017 Jan 13–15; Washington (DC).
- Markowitz JS, Patrick KS. The clinical pharmacokinetics of amphetamines utilized in the treatment of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017 Oct;27(8):678–689. PubMed PMID: 28910145.
- Bach MV, Coutts RT, Baker GB. Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719–732. PubMed PMID: 10456690.
- Haufroid V, Hantson P. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants. Clin Toxicol (Phila). 2015 Jul;53(6):501–510. PubMed PMID: 25998998.
- D’Souza S, Mayock S, Salt A. A review of in vivo and in vitro aspects of alcohol-induced dose dumping. AAPS. 2017;3(5):1–20.
- Childress AC, Wigal SB, Brams MN, et al. Efficacy and safety of amphetamine extended-release oral suspension in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2018 Jun;28(5):306–313. PubMed PMID: 29211967; PubMed Central PMCID: PMCPMC5994670.
- Kaufman J, Birmaher B, Brent D, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980–988. PubMed PMID: 9204677.
- Wigal SB, Gupta S, Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull. 1998;34(1):47–53. PubMed PMID: 9564198.
- Childress AC, Kando JC, King TR, et al. Early-onset efficacy and safety pilot study of amphetamine extended-release oral suspension in the treatment of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2019 Feb;29(1):2–8. PubMed PMID: 30575407; PubMed Central PMCID: PMCPMC6362322.
- Chen A, Jason M, Munoz M. Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Pediatric Postmarketing Pharmacovigilance Review. [cited 2019 Apr 20]. Available from: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM610726.pdf
- Childress AC, Kando JC, King TR, et al. Early-onset efficacy and safety pilot study of amphetamine extended-release oral suspension in the treatment of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2018 Dec 21. PubMed PMID: 30575407. DOI:10.1089/cap.2018.0078.
- Dyanavel XR [cited 2019 Apr 20]. Available from: https://www.goodrx.com/dyanavel-xr?dosage=2.5mg-ml&form=oral-suspension&label_override=Dyanavel+XR&quantity=180
- Adderall XR Prices, Coupons & Patient Assistance [cited 2019 Apr 20]. Available from: https://www.goodrx.com/adderall-xr
- Neos Therapeutics Poprietary Technology. Available from: https://www.neostx.com/proprietary-pharmaceutical-technologies/
- Adzenys XR-ODT (amphetamine extended-release orallydisintegrating tablets), CII. Highlights of Prescribing Information. [cited 2019 June 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204326s000lbl.pdf
- Mathew S. Center for Drug Evaluation and Research Application Number: 204326orig1s000 Pharmacology Review(s) [cited 2019 Apr 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/204326Orig1s000PharmR.pdf
- Adzenys ER (Amphetamine) extended-release oral suspension, CII. Highlights of Prescribing Information. [cited 2019June 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204325s000lbl.pdf
- Cotempla XR-ODT (Methylphenidate extended-release orally disintegrating tablets), CII. Highlights of Prescribing Information. [cited 2019 June 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205489s000lbl.pdf
- QUILLICHEW ER™ (Methylphenidate hydrochloride) extended-release chewable tablets, for oral use, CII. Highlights of Prescribing Information. [cited 2019 30 June]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207960s005lbl.pdf
- Stein MA, Waldman ID, Charney E, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011 Dec;21(6):581–588. PubMed PMID: 22136094; PubMed Central PMCID: PMCPMC3243461.
- Bonvicini C, Faraone SV, Scassellati C. Attention-deficit hyperactivity disorder in adults: a systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies. Mol Psychiatry. 2016 Jul;21(7):872–884. PubMed PMID: 27217152; PubMed Central PMCID: PMCPMC5414093.